Megan Houweling
Overview
Explore the profile of Megan Houweling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kucukosmanoglu A, Scoarta S, Houweling M, Spinu N, Wijnands T, Geerdink N, et al.
Clin Cancer Res
. 2024 Apr;
30(8):1685-1695.
PMID: 38597991
Purpose: Combination therapies are a promising approach for improving cancer treatment, but it is challenging to predict their resulting adverse events in a real-world setting. Experimental Design: We provide here...
2.
Giczewska A, Pastuszak K, Houweling M, Abdul K, Faaij N, Wedekind L, et al.
Neurooncol Adv
. 2023 Dec;
5(1):vdad134.
PMID: 38047207
Background: In recent years, drug combinations have become increasingly popular to improve therapeutic outcomes in various diseases, including difficult to cure cancers such as the brain cancer glioblastoma. Assessing the...
3.
Houweling M, Giczewska A, Abdul K, Nieuwenhuis N, Kucukosmanoglu A, Pastuszak K, et al.
Neurooncol Adv
. 2023 Jul;
5(1):vdad073.
PMID: 37455945
Background: IDH-wildtype glioblastoma (GBM) is a highly malignant primary brain tumor with a median survival of 15 months after standard of care, which highlights the need for improved therapy. Personalized...
4.
Brahm C, Abdul U, Houweling M, van Linde M, Lagerweij T, Verheul H, et al.
Neurooncol Adv
. 2021 Jan;
2(1):vdaa151.
PMID: 33392504
Background: Patients with glioblastoma (GBM) have a dismal prognosis, and there is an unmet need for new therapeutic options. This study aims to identify new therapeutic targets in GBM. Methods:...
5.
Saleem H, Abdul U, Kucukosmanoglu A, Houweling M, Cornelissen F, Heiland D, et al.
Drug Resist Updat
. 2019 May;
43:29-37.
PMID: 31054489
Targeted therapy against driver mutations responsible for cancer progression has been shown to be effective in many tumor types. For glioblastoma (GBM), the epidermal growth factor receptor (EGFR) gene is...
6.
Weigand K, Schirris T, Houweling M, van den Heuvel J, Koenderink J, Dankers A, et al.
Toxicol In Vitro
. 2019 Jan;
56:52-61.
PMID: 30639138
Chronic kidney disease (CKD) is accompanied by accumulating levels of uremic solutes in the circulation. Changes in the size and composition of the bile acid pool have also been observed....
7.
Abdul K, Houweling M, Svensson F, Narayan R, Cornelissen F, Kucukosmanoglu A, et al.
Drug Resist Updat
. 2018 Nov;
40:17-24.
PMID: 30439622
Glioblastoma is the most common and malignant form of brain cancer, for which the standard treatment is maximal surgical resection, radiotherapy and chemotherapy. Despite these interventions, mean overall survival remains...